Review



pt2 shp53 plasmid  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc pt2 shp53 plasmid
    Pt2 Shp53 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2-shP53+(Plasmid+%23124261)/pmc12824223-519-24-29
    Average 93 stars, based on 10 article reviews
    pt2 shp53 plasmid - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Injection:

    Article Title: SNORA49 negatively regulates self-renewal of liver cancer stem cells and hepatocarcinogenesis via suppressing SOX9 transcription
    Article Snippet: Alb-Cre mice were obtained from GemPharmatech Co., Ltd, and LSL-Cas9 mice were from Jackson Laboratory. .. 8-week-old mice with C57BL/6 background were injected with 0.9% NaCl solution containing 20 μg of pBABE-c-mycT58A+HRasG12V plasmid (Catalog No. 11130, Addgene), 20 μg of pT2-shP53 plasmid (Catalog No. 124261, Addgene) and 20 μg of pT2/C-Luc//PGK-SB13 plasmid (Catalog No. 20207, Addgene). ..

    Article Title: SNORA74A Drives Self‐Renewal of Liver Cancer Stem Cells and Hepatocarcinogenesis Through Activation of Notch3 Signaling
    Article Snippet: .. To deliver the intrahepatic transposon system, experiments were conducted using 8‐week‐old mice, which were hydrodynamically injected through the tail vein with the following plasmids: 20 μg of pBABE‐c‐mycT58A+HRasG12 V plasmid (catalog number 11 130, Addgene), 20 μg of pT2‐shP53 plasmid (catalog number 124 261, Addgene), and 20 μg of a plasmid encoding firefly luciferase and SB transposase (catalog number 20 207, Addgene). ..

    Plasmid Preparation:

    Article Title: SNORA49 negatively regulates self-renewal of liver cancer stem cells and hepatocarcinogenesis via suppressing SOX9 transcription
    Article Snippet: Alb-Cre mice were obtained from GemPharmatech Co., Ltd, and LSL-Cas9 mice were from Jackson Laboratory. .. 8-week-old mice with C57BL/6 background were injected with 0.9% NaCl solution containing 20 μg of pBABE-c-mycT58A+HRasG12V plasmid (Catalog No. 11130, Addgene), 20 μg of pT2-shP53 plasmid (Catalog No. 124261, Addgene) and 20 μg of pT2/C-Luc//PGK-SB13 plasmid (Catalog No. 20207, Addgene). ..

    Article Title: SNORA74A Drives Self‐Renewal of Liver Cancer Stem Cells and Hepatocarcinogenesis Through Activation of Notch3 Signaling
    Article Snippet: .. To deliver the intrahepatic transposon system, experiments were conducted using 8‐week‐old mice, which were hydrodynamically injected through the tail vein with the following plasmids: 20 μg of pBABE‐c‐mycT58A+HRasG12 V plasmid (catalog number 11 130, Addgene), 20 μg of pT2‐shP53 plasmid (catalog number 124 261, Addgene), and 20 μg of a plasmid encoding firefly luciferase and SB transposase (catalog number 20 207, Addgene). ..

    Luciferase:

    Article Title: SNORA74A Drives Self‐Renewal of Liver Cancer Stem Cells and Hepatocarcinogenesis Through Activation of Notch3 Signaling
    Article Snippet: .. To deliver the intrahepatic transposon system, experiments were conducted using 8‐week‐old mice, which were hydrodynamically injected through the tail vein with the following plasmids: 20 μg of pBABE‐c‐mycT58A+HRasG12 V plasmid (catalog number 11 130, Addgene), 20 μg of pT2‐shP53 plasmid (catalog number 124 261, Addgene), and 20 μg of a plasmid encoding firefly luciferase and SB transposase (catalog number 20 207, Addgene). ..



    Similar Products

    pt2 shp53 plasmid  (Addgene inc)
    93
    Addgene inc pt2 shp53 plasmid
    Pt2 Shp53 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2-shP53+(Plasmid+%23124261)/pmc12824223-519-24-29
    Average 93 stars, based on 1 article reviews
    pt2 shp53 plasmid - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pt2 shp53 gfp4  (Addgene inc)
    93
    Addgene inc pt2 shp53 gfp4
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Pt2 Shp53 Gfp4, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pmc12452061-258-7-9
    Average 93 stars, based on 1 article reviews
    pt2 shp53 gfp4 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    shrna plasmid targeting p53  (Addgene inc)
    93
    Addgene inc shrna plasmid targeting p53
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Shrna Plasmid Targeting P53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pm40484249-262-1-8
    Average 93 stars, based on 1 article reviews
    shrna plasmid targeting p53 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    lenti efs biraopt gsq rbxn p2a blast  (Addgene inc)
    93
    Addgene inc lenti efs biraopt gsq rbxn p2a blast
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Lenti Efs Biraopt Gsq Rbxn P2a Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pm39972349-72-25-26
    Average 93 stars, based on 1 article reviews
    lenti efs biraopt gsq rbxn p2a blast - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pt2 shp53 gfp4 addgene  (Addgene inc)
    93
    Addgene inc pt2 shp53 gfp4 addgene
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Pt2 Shp53 Gfp4 Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pm39891906-265-174-175
    Average 93 stars, based on 1 article reviews
    pt2 shp53 gfp4 addgene - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ecori site mutated pt2 shp53 gfp4  (Addgene inc)
    93
    Addgene inc ecori site mutated pt2 shp53 gfp4
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Ecori Site Mutated Pt2 Shp53 Gfp4, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pmc11609384-213-8-12
    Average 93 stars, based on 1 article reviews
    ecori site mutated pt2 shp53 gfp4 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pt2 shp53  (Addgene inc)
    93
    Addgene inc pt2 shp53
    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / <t>shp53</t> HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.
    Pt2 Shp53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2-shP53+(Plasmid+%23124261)/pmc11306581-502-30-33
    Average 93 stars, based on 1 article reviews
    pt2 shp53 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    short hairpin rna targeting p53  (Addgene inc)
    93
    Addgene inc short hairpin rna targeting p53
    Figure 4. SNORA13 regulates <t>p53</t> activity through the nucleolar stress response pathway (A) Gene set enrichment analysis (GSEA) showing downregulation of the p53 pathway in SNORA13 knockout BJ-HRASG12V cells at baseline or after tamoxifen treatment. (B) RT-qPCR analysis of CDKN1A expression relative to GAPDH in wild-type BJ-HRASG12V cells or four independent SNORA13 knockout clones at baseline or after tamoxifen treatment. (legend continued on next page)
    Short Hairpin Rna Targeting P53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pt2+shp53+plasmid/pT2%2Fshp53%2FGFP4+(Plasmid+%2320208)/pm38981482-290-45-50
    Average 93 stars, based on 1 article reviews
    short hairpin rna targeting p53 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / shp53 HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.

    Journal: Disease Models & Mechanisms

    Article Title: Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs

    doi: 10.1242/dmm.052370

    Figure Lengend Snippet: siCtnnb1 and siAnln decreased tumor burden in the NRAS G12V / shp53 HCC model. (A) Schematic of NRAS G12V / shp53 mouse model receiving continuous siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age, i.e. start timepoint of 0 weeks (0w). Injections of siRNA (5 mg/kg) started 4 days later (0.5w) and continued every other week (2.5w, 4.5w, 6.5w). Mice were sacrificed 1 week after the fourth siRNA dose (7.5w). (B) Schematic of NRAS G12V / shp53 mouse model receiving transient siRNA injections. Male C57BL/6J mice underwent HDT injection at 8 weeks of age (0w). Injections of siRNA (5 mg/kg) started 4 days later and continued every other week for a total of two doses (0.5w and 2.5w). Mice were sacrificed 5 weeks after the second siRNA dose (7.5w). (C) Liver-to-body-weight ratios for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. (D) Gross liver images from NRAS G12V / shp53 mice after continuous (top three rows) and transient (bottom three rows) treatment with siRNA. (E) Quantification of surface tumors for NRAS G12V / shp53 mice after continuous (circles) and transient (triangles) siRNA treatment. For panels C and E, the P -values with respect to the PBS group are shown above each group.

    Article Snippet: T/Caggs-NRASV12 ( Addgene plasmid #20205 ) and pT2/shp53/GFP4 ( Addgene plasmid #20208 ) were gifts from John Ohlfest (University of Minnesota, MN, USA).

    Techniques: Injection

    Figure 4. SNORA13 regulates p53 activity through the nucleolar stress response pathway (A) Gene set enrichment analysis (GSEA) showing downregulation of the p53 pathway in SNORA13 knockout BJ-HRASG12V cells at baseline or after tamoxifen treatment. (B) RT-qPCR analysis of CDKN1A expression relative to GAPDH in wild-type BJ-HRASG12V cells or four independent SNORA13 knockout clones at baseline or after tamoxifen treatment. (legend continued on next page)

    Journal: Cell

    Article Title: A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence.

    doi: 10.1016/j.cell.2024.06.019

    Figure Lengend Snippet: Figure 4. SNORA13 regulates p53 activity through the nucleolar stress response pathway (A) Gene set enrichment analysis (GSEA) showing downregulation of the p53 pathway in SNORA13 knockout BJ-HRASG12V cells at baseline or after tamoxifen treatment. (B) RT-qPCR analysis of CDKN1A expression relative to GAPDH in wild-type BJ-HRASG12V cells or four independent SNORA13 knockout clones at baseline or after tamoxifen treatment. (legend continued on next page)

    Article Snippet: Male FVB/NJ mice were injected at 7 weeks of age with pT/Caggs-NRASV12 (Addgene #20205),80 SB100 transposase plasmid (pCMV-SB100), and either 1) sgControl plasmid (sgGFP/sgGal4), 2) SNORA13 homolog targeting pool 1 plasmids, 3) SNORA13 homolog targeting pool 2 plasmids, or 4) a Sleeping Beauty plasmid expressing short-hairpin RNA targeting p53 (pT2/shp53/GFP4; Addgene #20208).80 Plasmids were resuspended in 2 mL of saline and administered via tail vein injection in 7 seconds.

    Techniques: Activity Assay, Knock-Out, Quantitative RT-PCR, Expressing, Clone Assay